Diagnostics

A landmark study reveals GLP-1 drugs like Ozempic dramatically reduce risks of depression and anxiety, hinting at a new era for mental healthcare.

Following positive study results, BioPorto is moving its NGAL test for adult acute kidney injury toward FDA review, aiming to revolutionize early detection.

A new DoD-funded trial combines a biologic drug with a plant-based supplement, aiming to break treatment barriers for ulcerative colitis, a major military issue.

The company launches new research assays for pTau217, entering a competitive field aimed at replacing invasive tests with a simple blood draw.

With new execs from Grail and Eli Lilly, ClearNote Health signals a major push to get its AI-powered cancer detection tests through trials and into the market.

A new partnership combines large-scale strategy with clinical AI tech, offering a single path for healthcare systems to deploy AI amid a global staff crisis.

With veteran leader Brian McKelligon at the helm, Infinity Bio aims to commercialize its powerful MIPSA platform and redefine precision medicine.

A new AI-powered blood test for early liver cancer detection is now accessible nationwide through Quest Diagnostics, aiming to improve dismal screening rates.

How Robert Wood Johnson University Hospital eliminated a two-month backlog for sleep apnea testing, transforming patient care and offering a new healthcare model.

A new partnership seeks to conquer C. difficile, a deadly hospital infection that has stumped pharma giants, by advancing a novel dual-action vaccine.

Cority's new AI agents automate safety tasks, promising proactive risk prevention. But are EHS teams ready for the rapid, ungoverned adoption?

Student innovators unveil an AI lifeline for ICUs at Quest Global's Ingenium, tackling a critical medical crisis and showcasing India's engineering future.

New data shows firms with active board oversight of AI see huge ROI, yet most boards are disengaged. This governance gap is now a top business risk.

DNA Script's global expansion brings benchtop DNA printers to new markets, promising to accelerate research and decentralize biotech supply chains.

A new network for consumer ads is launching in 30,000 clinics, offering brands a trusted space but raising new questions about ethics and data privacy.

A new strategic partnership aims to unite California's life science hubs, creating a streamlined path to capital for medtech and biotech startups.

Activist investor Altai Capital launches a proxy fight at OraSure, alleging chronic underperformance and demanding board seats to force a strategic review.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

A simple blood test is revolutionizing Alzheimer's diagnosis. ALZpath's pTau217 antibody is now the industry benchmark, promising earlier detection for millions.